Interaction tamoxifène – clou de girofle : à propos d’un cas d’effet indésirable

Ouedraogo, 2020, Risk reduction in a cancer chemotherapy production unit: contribution of an automated drug dispensing system, J Oncol Pharm Pract Pouyanne, 2000, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, 320, 1036, 10.1136/bmj.320.7241.1036 Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, J Am Med Assoc, 279, 1200, 10.1001/jama.279.15.1200 Agence française de sécurité sanitaire et des produits de santé (AFSSAPS), 2011 Royaume du Maroc, Ministère de la Santé. Organisation du Système National de Pharmacovigilance. Circulaire No 003 du 04 janvier 2010 ;site internet : file:///C:/Users/Med/Downloads/Organisation%20du%20Syst%C3 %A8me%20National%20de%20Pharmacovigilance%20(3).pdf. (accès en date du 15/09/2020). Clairet, 2019, Interaction between phytotherapy and oral anticancer agents: prospective study and literature review, Med Oncol, 36, 45, 10.1007/s12032-019-1267-z Juanbeltz Zurbano, 2017, Complementary medicine use in cancer patients receiving intravenous antineoplastic treatment, Farma Hospital, 41, 589 Boon, 2000, Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions, J Clin Oncol, 18, 2515, 10.1200/JCO.2000.18.13.2515 Zeller, 2013, Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center, J Cancer Res Clin Oncol, 139, 357, 10.1007/s00432-012-1336-6 Arimone, 2011, Réactualisation de la méthode française d’imputabilité des effets indésirables des médicaments, Thérapies, 66, 517, 10.2515/therapie/2011073 Agence Nationale de Sécurité du Médicament et des produits de santé. Tamoxifene et fluoxétine ou paroxétine : pourquoi il est deconseillé de les associer – Point d’information. 22/06/2010 ; site internet : https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Tamoxifene-et-fluoxetine-ou-paroxetine-pourquoi-il-est-deconseille-de-les-associer-Point-d-information (accès en date du 15/07/2020). Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Res Treat, 85, 151, 10.1023/B:BREA.0000025406.31193.e8 Stearns, 2003, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine, J Natl Cancer Inst, 95, 1758, 10.1093/jnci/djg108 Base de données publique des médicaments. Résumé des Caracteristique du Produit. 12/07/2019 ; site internet : http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=60940205&typedoc=R (accès en date du 5/09/2020). Lobstein, 2017, Huile essentielle de clou de girofle, Actual Pharma, 56, 59 Chaieb, 2007, The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): a short review, Phytother Res, 21, 501, 10.1002/ptr.2124 Wright, 1995, Intravenous eugenol causes hemorrhagic lung edema in rats: proposed oxidant mechanisms, J Lab Clin Med, 125, 257 Brown, 1992, Disseminated intravascular coagulation and hepatocellular necrosis due to clove oil, Blood Coagul Fibrinolysis, 3, 665, 10.1097/00001721-199210000-00025 Soundran, 1994, Hepatotoxicity of eugenol, Anc Sci Life, 13, 213 Barbelet, 2015 Agence Nationale de Sécurité du Médicament et des produits de santé, 2019 Agence Nationale de Sécurité du Médicament et des produits de santé, 2010 Leung, 2012, Metabolic activation in drug-induced liver injury, Drug Metab Rev, 44, 18, 10.3109/03602532.2011.605791 Bolton, 2014, Quinone methide bioactivation pathway: contribution to toxicity and/or cytoprotection?, Curr Org Chem, 18, 61, 10.2174/138527281801140121123046 Watkins, 1998, Hepatic dysfunction associated with troglitazone, N Engl J Med, 338, 916, 10.1056/NEJM199803263381314 Furr, 1984, The pharmacology and clinical uses of tamoxifen, Pharmacol Ther, 25, 127, 10.1016/0163-7258(84)90043-3 Marques, 1997, Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide, Carcinogenesis, 18, 1949, 10.1093/carcin/18.10.1949 Atsumi, 2005, A comparative study of the antioxidant/prooxidant activities of eugenol and isoeugenol with various concentrations and oxidation conditions, Toxicol In Vitro, 19, 1025, 10.1016/j.tiv.2005.04.012 Kumaravelu, 1995, Effect of eugenol on drug-metabolizing enzymes of carbon tetrachloride-intoxicated rat liver, Biochem Pharmacol, 49, 1703, 10.1016/0006-2952(95)00083-C Han, 2007, Eugenol inhibit 7, 12-dimethylbenz [a] anthracene-induced genotoxicity in MCF-7 cells: bifunctional effects on CYP1 and NAD (P) H: quinone oxidoreductase, FEBS Lett, 581, 749, 10.1016/j.febslet.2007.01.044 Ross, 2000, NAD (P) H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms, Chem Biol Interact, 129, 77, 10.1016/S0009-2797(00)00199-X Aggarwal, 2006, Molecular targets of dietary agents for prevention and therapy of cancer, Biochem Pharmacol, 71, 1397, 10.1016/j.bcp.2006.02.009 Pramod, 2010, Eugenol: a natural compound with versatile pharmacological actions, Nat Prod Commun, 5, 1999 Dunlap, 2012, Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide, Chem Res Toxicol, 25, 2725, 10.1021/tx3003609 Bodell, 1998, Oxidation of eugenol to form DNA adducts and 8-hydroxy-2’-deoxyguanosine: role of quinone methide derivative in DNA adduct formation, Carcinogenesis, 19, 437, 10.1093/carcin/19.3.437